Vulcan releases maiden Indicated Resource at Insheim
Vulcan Energy Resources Ltd (ASX:VUL) has announced the maiden Indicated Lithium-Brine Mineral Resource Estimate at the Insheim Licence in the Upper Rhine Valley of South-West Germany.
The Insheim Exploration Licence has been classified as an Indicated Resource because of the binding Memorandum of Understanding between Vulcan and Pfalzwerke geofuture GmbH, which permits access to the Permo-Triassic aquifer brine, and the enhanced understanding of the Insheim subsurface geology via seismic and well log data.
The maiden Indicated Vulcan Lithium-Brine Resource estimation for the Insheim Licence is estimated at 136,000 tonnes of elemental lithium as indicated below.
It should be noted that mineral resources are not mineral reserves and do not have demonstrated economic viability. There is no guarantee that all or any part of the mineral resource will be converted into a mineral reserve.
Vulcan has acquired direct access to lithium-enriched brine at the operating Insheim Geothermal Plant and Insheim Exploitation Licence via the MoU with Pfalzwerke geofuture GmbH.
The Insheim Geothermal Plant is currently pumping hot, high-flow, lithium-enriched brine from aquifer depths of nearly 3000 metres to the surface for power generation.
Pfalzwerke geofuture GmbH is not processing or extracting lithium as part of the power generation circuit before the reinjecting the brine into the reservoir.
The MoU grants Vulcan an initial collaboration period that allows access to the Insheim Licence brine and data, with a pathway to construct a lithium extraction demonstration plant at Insheim in the future.
The agreement marks a material milestone for Vulcan as the company has obtained access and a pathway to co-production lithium rights to lithium-enriched brine from within the deep aquifer underlying the Insheim Exploitation Licence.
As indicated below, the Insheim Licence is 19 square kilometres and brings Vulcan’s total land position in the Upper Rhine Graben to 807.19 square kilometres.
More from Finfeed
Creso delivers second consecutive quarter of record revenue growth
Jul 1, 2021
Creso Pharma (ASX: CPH) has achieved strong sales growth for the June quarter generating a total of A$1,715,933 - a 24% increase on the previous quarter (Q1 CY2021: A$1,385,000).
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
Publishers Notice
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.
